TSMC stock jumps 5% premarket after Goldman lifts target; earnings countdown starts

TSMC stock jumps 5% premarket after Goldman lifts target; earnings countdown starts

New York, Jan 5, 2026, 05:56 EST — Premarket

  • TSMC’s U.S.-listed shares rose more than 5% in premarket trade, tracking a record move in Taipei.
  • Goldman Sachs raised its price target on the chipmaker, flagging tight capacity and strong AI-driven demand.
  • Investors now look to TSMC’s December sales update on Jan. 9 and quarterly results on Jan. 15.

Shares of Taiwan Semiconductor Manufacturing Co. (TSMC) climbed 5.2% to $319.61 in U.S. premarket trading on Monday, after the chipmaker’s Taipei-listed stock hit a fresh record on a Goldman Sachs target hike. Investing

The move matters because TSMC is the world’s largest contract chipmaker — a “foundry” that manufactures chips designed by others — and its order book is treated as a read-through on global demand for high-end processors used in data centres. Asia’s tech-heavy markets have started 2026 with renewed momentum as investors position for another year of heavy spending on artificial intelligence infrastructure. Reuters

Investors also have near-term catalysts in view. TSMC’s investor relations calendar shows a December 2025 monthly sales update due on Jan. 9, followed by its fourth-quarter 2025 earnings conference on Jan. 15. TSMC

Goldman lifted its target price on TSMC to NT$2,330 from NT$1,720 and reiterated a “conviction buy” rating, an Investing.com report said. The report said the bank expects fast growth in AI-related computing to keep “silicon demand” — demand for chips — ahead of supply well into 2027. Investing

Goldman Sachs analyst Bruce Lu called AI a “multi-year growth engine,” according to TipRanks, as he raised his target and lifted earnings estimates. TipRanks

Goldman also expects TSMC to spend more than $150 billion in capital expenditure from 2026 to 2028 to add capacity, while forecasting continued tightness in 3-nanometre and 5-nanometre “wafer” capacity — the silicon discs chips are built on — through 2026 and 2027, Investing.com said. Investing

In Taipei, TSMC shares jumped as much as 7% to a record NT$1,695 and extended a run of record highs over the past two sessions, the same report said. Investing

Separately, Taiwanese prosecutors said they had filed additional charges against the Taiwan unit of Tokyo Electron and others over alleged theft of TSMC trade secrets, expanding a case that first surfaced last year. Tokyo Electron said its parent company had not been indicted and the situation did not affect its financial results. Reuters

The risk for bulls is that expectations run ahead of what TSMC can deliver in its next guidance update, particularly on pricing, capacity expansion and margins as it ramps overseas production. Any shift in the pace of AI infrastructure spending or new trade friction affecting chip supply chains could also test sentiment.

The next hard markers are TSMC’s December monthly sales release on Jan. 9 and its Jan. 15 earnings conference, when investors will parse its 2026 outlook for revenue growth, capital spending and capacity constraints. TSMC

Stock Market Today

  • Summit Therapeutics valuation under the microscope after share strength; P/B at 74.8x, DCF fair value $217.67
    January 7, 2026, 8:37 PM EST. Summit Therapeutics (SMMT) rose 1.9% on the day and 8.7% over the week, though longer-term returns remain uneven: 30 days up 2.07%, 90 days down 16.07%, and a three-year total shareholder return that highlights patient holders' gains despite near-term momentum cooling. On a P/B basis, the stock trades at 74.8x price against a US$19.01 share price, far above the industry average of 2.7x and a peer average of 11.2x, signaling the market expects a stronger future than the balance sheet implies. A DCF model puts fair value at US$217.67 versus last close of US$19.01, suggesting potential discount based on cash flow scenarios. The narrative flags OVERVALUED P/B and UNDERVALUED DCF; risk remains, including ongoing net losses of US$921.617 and potential ivonescimab trial failures.
Saudi Aramco stock dips again as oil eases — traders eye Feb 1 OPEC+ meeting, March 10 results
Previous Story

Saudi Aramco stock dips again as oil eases — traders eye Feb 1 OPEC+ meeting, March 10 results

ASML Holding stock pops on Bernstein upgrade as €1,300 target turns heads before Jan. 28 earnings
Next Story

ASML Holding stock pops on Bernstein upgrade as €1,300 target turns heads before Jan. 28 earnings

Go toTop